World's Largest Vaccine Manufacturer: Serum Institute of India (SII)

Serum Institute of India Pvt Ltd (SIIPL) Emerges as the Global Leader in Vaccine Manufacturing
Ranked as the world's largest vaccine manufacturer by the number of doses produced and sold globally, SIIPL's impact on global health is paramount. With over 1.5 billion doses supplied to around 170 countries, SIIPL has become a cornerstone in the global vaccination effort.

Founding and Mission of SIIPL

Founded in 1966 with the aim of manufacturing lifesaving immunobiological drugs, SIIPL has been committed to global health advocacy since its inception. Its primary mission has been to bring affordable and efficacious vaccines to the masses, ensuring that the world's most vulnerable populations have access to the latest and most trusted vaccine technologies.

Comprehensive Vaccine Portfolio

SIIPL's portfolio includes a wide range of vaccines that have significantly contributed to the global fight against various diseases. Major vaccines produced by SII include:

Diphtheria Tetanus Pertussis (DTaP): A combined vaccine that protects against three serious diseases: diphtheria, tetanus, and pertussis. Hib (Haemophilus influenzae type b): An intramuscular vaccine aiming to protect against pertussis, diphtheria, tetanus, and Haemophilus influenzae b. BCG (Bacille Calmette-Guérin): Protects against tuberculosis by using a live attenuated form of the bacterium Mycobacterium bovis. recombinant Hepatitis B (HBV): Utilizing recombinant DNA technology, this vaccine stimulates the immune system to produce antibodies against the Hepatitis B virus. Measles Mumps and Rubella (MMR): A combined vaccine that protects against three different viruses: measles, mumps, and rubella.

Commitment to Affordable Vaccines

SIIPL's dedication to affordability is evident in its efforts to bring down the prices of newer vaccines. This commitment not only ensures that life-saving vaccines reach more people but also contributes to the overall goal of global health equity. By doing so, SIIPL plays a crucial role in reducing the burden of preventable diseases worldwide.

Current Developments in Vaccine Manufacturing

Most recently, SIIPL has been involved in the production of experimental coronavirus vaccines, which includes 40 million units of Oxford's vaccine currently under trial. Despite these efforts, the effectiveness of the vaccine is still being evaluated, highlighting the ongoing advancements in vaccine technology.

Conclusion

As one of the most prolific vaccine manufacturers globally, Serum Institute of India continues to innovate and serve the public interest through its commitment to global health. Whether it's producing affordable vaccines or working on cutting-edge research, SIIPL remains at the forefront of the global vaccine manufacturing landscape.